Science Advisory and Grant Review Board
Telethon Institute of Genetics and Medicine
Dr. Andrés Klein’s research interests include uncovering the genetic and cellular basis of phenotypic variability as a way for identifying novel therapeutic targets for genetic diseases. His work has led to the discovery of potential treatments for two of them, using FDA-approved drugs. Recently he has been modeling diseases in many mouse strains for precision medicine studies.
Andrés Klein received his B.Sc in Biochemistry and his PhD in Cellular and Molecular Biology at the Pontificia Universidad Católica de Chile where he studied the cell death mechanisms involved in Niemann-Pick type C (NPC) brain degeneration. Dr. Klein did a postdoc at Stanford University (2009-2011) where he developed novel mouse models for studying the relevance of different cell types for NPC disease pathology and a second postdoc (2011-2015) at the Weizmann Institute of Science uncovering modifier genes of Gaucher disease progression. Currently he is working at the Telethon Institute of Genetics and Medicine where he is applying cutting edge technologies, such as exome sequencing plus multi-omics, for the identification of modifier genes of disease progression and biomarkers.
Dr. Klein has been endorsed by several institutions including Pew Charitable Trust (2009-2011), Ara Parseghian Medical Research Foundation (2009-2011), and the UK Gaucher Association (2011-2013).
Dr. Klein was awarded with the young Chilean innovator prize by MIT technology reviews (2013) and he was selected as one of the top 100 young Chilean leaders of 2013. He has received grants from several international organizations including the Rosetrees of Trust, Cure & Action for Tay-Sachs disease and Horizon 2020.